Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Golomb Gershon

Researchers

 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Aizik G, Waiskopf N, Agbaria M, Ben-David-Naim M, Nordling-David MM, Jbara-Agbaria D, et al. Targeting and imaging of monocyte-derived macrophages in rat's injured artery following local delivery of liposomal quantum dots. J Control Release 2020;318:145-157.

(2) Aizik G, Waiskopf N, Agbaria M, Ben-David-Naim M, Levi-Kalisman Y, Shahar A, et al. Liposomes of Quantum Dots Configured for Passive and Active Delivery to Tumor Tissue. Nano Lett 2019;19(9):5844-5852.

(3) Grad E, Gutman D, Golomb M, Efraim R, Oppenheim A, Richter I, et al. Monocyte Modulation by Liposomal Alendronate Improves Cardiac Healing in a Rat Model of Myocardial Infarction. Regen Eng Transl Med 2019;5(3):280-289.

(4) Ben-David-Naim M, Dagan A, Grad E, Aizik G, Nordling-David MM, Clyne AM, et al. Targeted siRNA nanoparticles for mammary carcinoma therapy. Cancers 2019;11(4).

(5) Chorny M, Levy RJ, Golomb G. Cardiovascular delivery of drugs and biotherapeutics. Drug Deliv Transl Res 2018;8(4):865-867.

(6) Aizik G, Grad E, Golomb G. Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases. Drug Deliv Transl Res 2018;8(4):868-882.

(7) Grad E, Zolotarevsky K, Danenberg HD, Nordling-David MM, Gutman D, Golomb G. The role of monocyte subpopulations in vascular injury following partial and transient depletion. Drug Deliv Transl Res 2018;8(4):945-953.

(8) Ben David-Naim M, Grad E, Aizik G, Nordling-David MM, Moshel O, Granot Z, et al. Polymeric nanoparticles of siRNA prepared by a double-emulsion solvent-diffusion technique: Physicochemical properties, toxicity, biodistribution and efficacy in a mammary carcinoma mice model. Biomaterials 2017;145:154-167.

(9) Nordling-David MM, Yaffe R, Guez D, Meirow H, Last D, Grad E, et al. Liposomal temozolomide drug delivery using convection enhanced delivery. J Control Release 2017;261:138-146.

(10) Aizik G, Waiskopf N, Agbaria M, Levi-Kalisman Y, Banin U, Golomb G. Delivery of Liposomal Quantum Dots via Monocytes for Imaging of Inflamed Tissue. ACS Nano 2017;11(3):3038-3051.

(11) Ron-Doitch S, Sawodny B, Kühbacher A, David MMN, Samanta A, Phopase J, et al. Reduced cytotoxicity and enhanced bioactivity of cationic antimicrobial peptides liposomes in cell cultures and 3D epidermis model against HSV. J Control Release 2016;229:163-171.

(12) Epstein H, Afergan E, Koroukhov N, Eisenberg G, Gutman D, Golomb G. Liposomal bisphosphonates for the treatment of restenosis. Liposome Technology: Third Edition; 2016. p. 187-206.

(13) Effects of radical oxygen species and antioxidants on macrophage polarization. 2015 41st Annual Northeast Biomedical Engineering Conference, NEBEC 2015; 2015.

(14) Burwitz BJ, Reed JS, Hammond KB, Ohme MA, Planer SL, Legasse AW, et al. Technical advance: Liposomal alendronate depletes monocytes and macrophages in the nonhuman primate model of human disease. J Leukocyte Biol 2014;96(3):491-501.

(15) Nordling-David MM, Golomb G. Gene delivery by liposomes. Isr J Chem 2013;53(9-10):737-747.

(16) Gutman D, Golomb G. Liposomal alendronate for the treatment of restenosis. J Control Release 2012;161(2):619-627.

(17) Reufsteck C, Lifshitz-Shovali R, Zepp M, Bäuerle T, Kübler D, Golomb G, et al. Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions. Clin Exp Metastasis 2012;29(5):441-456.

(18) Gutman D, Epstein-Barash H, Tsuriel M, Golomb G. Alendronate liposomes for antitumor therapy: Activation of γδ T cells and inhibition of tumor growth. Adv Exp Med Biol 2012;733:165-179.

(19) Chan JM, Rhee J-, Drum CL, Bronson RT, Golomb G, Langer R, et al. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci U S A 2011;108(48):19347-19352.

(20) Gutman D, Epstein-Barash H, Tsuriel M, Golomb G. Alendronate liposomes for antitumor therapy: Activation of γδ T cells and inhibition of tumor growth. Adv Exp Med Biol 2011;733:165-179.

(21) Afergan E, Najajreh Y, Gutman D, Epstein H, Elmalak O, Golomb G. 31P-NMR and differential scanning calorimetry studies for determining vesicle's drug physical state and fraction in alendronate liposomes. J Bioanal Biomed 2010;2(6):125-131.

(22) Haber E, Afergan E, Epstein H, Gutman D, Koroukhov N, Ben-David M, et al. Route of administration-dependent anti-inflammatory effect of liposomal alendronate. J Control Release 2010;148(2):226-233.

(23) Epstein-Barash H, Gutman D, Markovsky E, Mishan-Eisenberg G, Koroukhov N, Szebeni J, et al. Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J Control Release 2010;146(2):182-195.

(24) Afergan E, David MB, Epstein H, Koroukhov N, Gilhar D, Rohekar K, et al. Liposomal simvastatin attenuates neointimal hyperplasia in rats. AAPS Journal 2010;12(2):181-187.

(25) Elazar V, Adwan H, Bäuerle T, Rohekar K, Golomb G, Berger MR. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int J Cancer 2010;126(7):1749-1760.

(26) Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A 2010;107(5):2213-2218.

(27) Cohen-Sela E, Chorny M, Gutman D, Komemi S, Koroukhov N, Golomb G. Characterization of monocytes-targeted nanocarriers biodistribution in leukocytes in ex-vivo and in-vivo models. Nano Biomed Eng 2010;2(2):91-99.

(28) Elazar V, Adwan H, Rohekar K, Zepp M, Lifshitz-Shovali R, Berger MR, et al. Biodistribution of antisense nanoparticles in mammary carcinoma rat model. Drug Deliv 2010;17(6):408-418.

(29) Breuer E, Chorghade MS, Fischer J, Golomb G. Glossary of terms related to pharmaceutics (IUPAC Recommendations 2009). Pure Appl Chem 2009;81(5):971-999.

(30) Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release 2009;133(2):90-95.

(31) Gutman D, Epstein H, Koroukhov N, Golomb G. Liposomal delivery system of adenosine for modulating inflammation. J Drug Deliv Sci Technol 2009;19(4):257-262.

(32) Haber E, Danenberg HD, Koroukhov N, Ron-El R, Golomb G, Schachter M. Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model. Hum Reprod 2009;24(2):398-407.

(33) Afergan E, Epstein H, Koroukhov N, Klein M, Litchi A, Mishani E, et al. Biodistribution and imaging studies of 67Ga-labeled liposomes in rabbits with a vascular injury. J Drug Deliv Sci Technol 2009;19(4):263-268.

(34) Cohen-Sela E, Teitlboim S, Chorny M, Koroukhov N, Danenberc HD, Gao J, et al. Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: Formulations of mithramycin and bioactivity. J Pharm Sci 2009;98(4):1452-1462.

(35) Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD, et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release 2008;132(2):84-90.

(36) Epstein H, Gutman D, Cohen-Sela E, Haber E, Elmalak O, Koroukhov N, et al. Preparation of alendronate liposomes for enhanced stability and bioactivity: In vitro and in vivo characterization. AAPS Journal 2008;10(4):505-515.

(37) Epstein H, Grad E, Golomb M, Koroukhov N, Edelman ER, Golomb G, et al. Innate immunity has a dual effect on vascular healing: Suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge. Atherosclerosis 2008;199(1):41-46.

(38) Markovsky E, Koroukhov N, Golomb G. Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomedicine 2007;2(4):545-553.

(39) Epstein H, Berger V, Levi I, Eisenberg G, Koroukhov N, Gao J, et al. Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J Control Release 2007;117(3):322-332.

(40) Cohen-Sela E, Dangoor D, Epstein H, Gati I, Danenberg HD, Golomb G, et al. Nanospheres of a bisphosphonate attenuate intimal hyperplasia. J Nanosci Nanotechnol 2006;6(9-10):3226-3234.

(41) Chorny M, Mishaly D, Leibowitz A, Domb AJ, Golomb G. Site-specific delivery of dexamethasone from biodegradable implants reduces formation of pericardial adhesions in rabbits. J Biomed Mater Res Part A 2006;78(2):276-282.

(42) Cohen-Sela E, Rosenzweig O, Gao J, Epstein H, Gati I, Reich R, et al. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release 2006;113(1):23-30.

(43) Epstein H, Afergan E, Moise T, Richter Y, Rudich Y, Golomb G. Number-concentration of nanoparticles in liposomal and polymeric multiparticulate preparations: Empirical and calculation methods. Biomaterials 2006;27(4):651-659.

(44) Banai S, Chorny M, Gertz SD, Fishbein I, Gao J, Perez L, et al. Erratum: Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries (Biomaterials (2005) 26 (451-461) DOI: 10.1016/j.biomaterials.2004.02. 040). Biomaterials 2005;26(23):4898-4901.

(45) Bejjani RA, BenEzra D, Cohen H, Rieger J, Andrieu C, Jeanny J-, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vision 2005;11:124-132.

(46) Banai S, Chorny M, Gertz SD, Fishbein I, Gao J, Perez L, et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 2005;26(4):451-461.

(47) Banai S, Gertz SD, Gavish L, Chorny M, Perez LS, Lazarovichi G, et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res 2004;64(1):165-171.

(48) Cohen-Sacks H, Elazar V, Gao J, Golomb A, Adwan H, Korchov N, et al. Delivery and expression of pDNA embedded in collagen matrices. J Control Release 2004;95(2):309-320.

(49) Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 2004;24(5):1235-1244.

(50) Danenberg HD, Golomb G, Groothuis A, Gao J, Epstein H, Swaminathan RV, et al. Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits. Circulation 2003;108(22):2798-2804.

(51) Danenberg HD, Fishbein I, Epstein H, Waltenberger J, Moerman E, Mönkkönen J, et al. Systemic Depletion of Macrophages by Liposomal Bisphosphonates Reduces Neointimal Formation Following Balloon-Injury in the Rat Carotid Artery. J Cardiovasc Pharmacol 2003;42(5):671-679.

(52) Gazit A, Yee K, Uecker A, Böhmer F-, Sjöblom T, Östman A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem 2003;11(9):2007-2018.

(53) Pipp F, Heil M, Issbrücker K, Ziegelhoeffer T, Martin S, Den Heuvel JV, et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: Evidence for a monocyte-mediated mechanism. Circ Res 2003;92(4):378-385.

(54) Cohen-Sacks H, Najajreh Y, Tchaikovski V, Gao G, Elazer V, Dahan R, et al. Novel PDGFβR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther 2002;9(23):1607-1616.

(55) Karck M, Meliss R, Hestermann M, Mengel M, Pethig K, Levitzki A, et al. Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation 2002;74(9):1335-1341.

(56) Chorny M, Fishbein I, Danenberg HD, Golomb G. Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods. J Control Release 2002;83(3):401-414.

(57) Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: Effect of formulation variables on size, drug recovery and release kinetics. J Control Release 2002;83(3):389-400.

(58) Danenberg HD, Fishbein I, Gao J, Mönkkönen J, Reich R, Gati I, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002;106(5):599-605.

(59) Stepensky D, Golomb G, Hoffman A. Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci 2002;91(2):508-516.

(60) Margolin L, Fishbein I, Banai S, Golomb G, Reich R, Perez LS, et al. Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: Augmentative effect of αvβ3 receptor blockade. Atherosclerosis 2002;163(2):269-277.

(61) Fishbein I, Brauner R, Chorny M, Gao J, Chen X, Laks H, et al. Local delivery of mithramycin restores vascular reactivity and inhibits neointimal formation in injured arteries and vascular grafts. J Control Release 2001;77(3):167-181.

(62) Hoffman A, Stepensky D, Ezra A, Van Gelder JM, Golomb G. Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm 2001;220(1-2):1-11.

(63) Fishbein I, Chorny M, Banai S, Levitzki A, Danenberg HD, Gao J, et al. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol 2001;21(9):1434-1439.

(64) Chen R, Schlossman A, Breuer E, Hagele G, Tillmann C, Van Gelder JM, et al. Long-chain functional bisphosphonates: synthesis, anticalcification, and antiresorption activity. Heteroatom Chem 2000;11(7):470-479.

(65) Ezra A, Hoffman A, Breuer E, Alferiev IS, Mönkkönen J, El Hanany-Rozen N, et al. A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem 2000;43(20):3641-3652.

(66) Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000;42(3):175-195.

(67) Fishbein I, Chorny M, Rabinovich L, Banai S, Gati I, Golomb G. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J Control Release 2000;65(1-2):221-229.

(68) Chorny M, Fishbein I, Golomb G. Drug delivery systems for the treatment of restenosis. Crit Rev Ther Drug Carrier Syst 2000;17(3):249-284.

(69) Fishbein I, Chorny M, Golomb G. Treatment of restenosis by controlled-release delivery systems of tyrphostins. Drug Dev Res 2000;50(3-4):487-496.

(70) Yaffe A, Golomb G, Breuer E, Binderman I. The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. J Periodontol 2000;71(10):1607-1612.

(71) Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S, et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 2000;7(22):1896-1905.

(72) Grossmann G, Grossmann A, Ohms G, Breuer E, Chen R, Golomb G, et al. Solid-state NMR of bisphosphonates adsorbed on hydroxy apatite. Magn Reson Chem 2000;38(1):11-16.

(73) Fishbein I, Waltenberger J, Banai S, Rabinovich L, Chorny M, Levitzki A, et al. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol 2000;20(3):667-676.

(74) Fishbein I, Chorny M, Rabinovich L, Banai S, Gertz S, Levitzki A, et al. Formulation factors and in vivo characterization of nanoparticles in restenosis. Proc Control Release Soc 1999(26):54-55.

(75) Cohen H, Alferiev IS, Mönkkönen J, Seibel MJ, Pinto T, Ezra A, et al. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharm Res 1999;16(9):1399-1406.

(76) Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999;60(2):68-73.

(77) Yaffe A, Binderman I, Breuer E, Pinto T, Golomb G. Disposition of alendronate following local delivery in a rat jaw. J Periodontol 1999;70(8):893-895.

(78) Teomim D, Fishbien I, Golomb G, Orloff L, Mayberg M, Domb AJ. Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. J Control Release 1999;60(1):129-142.

(79) Cohen H, Golomb G, Levy RJ. Gene delivery by polymer-encapsulated DNA. Proc Control Release Soc 1999(26):1136-1137.

(80) Danenberg HD, Monkkonen J, Fishbein I, Gati I, Chorny M, Banai S, et al. Controlled release of drugs from multiparticulate delivery systems in animal models of restenosis. Proc Control Release Soc 1999(26):52-53.

(81) Cohen H, Chen W, Golomb G, Levy RJ. DNA nanoparticle for gene transfer. Proc Control Release Soc 1998(25):374-375.

(82) Cohen H, Solomon V, Alferiev IS, Breuer E, Ornoy A, Patlas N, et al. Bisphosphonates and tetracycline: Experimental models for their evaluation in calcium-related disorders. Pharm Res 1998;15(4):606-613.

(83) Klein BY, Ben-Bassat H, Breuer E, Solomon V, Golomb G. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J Cell Biochem 1998;68(2):186-194.

(84) Ezra A, Hoffman A, Breuer E, Weiss G, Golomb G. Proteins: Carrier-mediated absorption of bisphosphonate prodrugs. Proc Control Release Soc 1998(25):473-474.

(85) Mathew M, Fowler BO, Breuer E, Golomb G, Alferiev IS, Eidelman N. Synthesis, Characterization, and Crystal Structure of Dicalcium Glutarylbis(phosphonate) Dihydrate: A Covalently Pillared Layer Structure with the Potential for Epitaxial Growth on Hydroxyapatite. Inorg Chem 1998;37(25):6485-6494.

(86) Chorny M, Fishbein I, Banai S, Levitzki A, Gertz SD, Rabinovich L, et al. In vitro and in vivo characteristics of tyrosine kinase inhibitor-containing PLA nanoparticles. Proc Control Release Soc 1998(25):667-668.

(87) Golomb G, Fishbein I. Tyrphostins, inhibitors of protein tyrosine kinase, in restenosis. Adv Drug Deliv Rev 1997;24(1):53-62.

(88) Orloff LA, Domb AJ, Teomim D, Fishbein I, Golomb G. Biodegradable implant strategies for inhibition of restenosis. Adv Drug Deliv Rev 1997;24(1):3-9.

(89) Mishaly D, Fishbein I, Moscovitz D, Golomb G. Site-specific delivery of colchicine in rat carotid artery model of restenosis. J Control Release 1997;45(1):65-73.

(90) Patashnik S, Rabinovich L, Golomb G. Preparation and evaluation of chitosan microspheres containing bisphosphonates. J DRUG TARGETING 1997;4(6):371-380.

(91) Patlas N, Yaffe P, Kimyagarov A, Golomb G, Ornoy A. Effects of continuous or cyclic administration of pamidronate on the skeleton in intact and oophorectomized young rats; Cells Tissues Organs 1997;159(1):42-47.

(92) Ezra A, Hoffman A, Breuer E, Weiss G, Lipka E, Amidon GL, et al. Peptidyl prodrugs for improved oral absorption. PROC CONTROL RELEASE SOC 1997(24):243-244.

(93) Brauner R, Laks H, Drinkwater D.C. J, Chaudhuri G, Shvarts O, Drake T, et al. Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts. J Thorac Cardiovasc Surg 1997;114(1):53-63.

(94) Golomb G, Fishbein I, Moscovitz D, Gertz SD, Levitzki A, Pearle A, et al. Inhibitors of protein tyrosine kinase for site specific therapy of restenosis. PROC CONTROL RELEASE SOC 1997(24):187-188.

(95) Van Gelder JM, Breuer E, Schlossman A, Ornoy A, Mönkkönen J, Similä J, et al. In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages. J Pharm Sci 1997;86(3):283-289.

(96) Fishbein I, Banai S, Levitzki A, Moscovitz D, Gertz SD, Gazit A, et al. Perivascular and intraluminal delivery systems of a tyrphostin for the treatment of restenosis. PROC CONTROL RELEASE SOC 1996(23):17-18.

(97) Golomb G, Fishbein I, Banai S, Mishaly D, Moscovitz D, Gertz SD, et al. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis 1996;125(2):171-182.

(98) Skrtic D, Eidelman N, Golomb G, Breuer E, Eanes ED. In vitro inhibition of membrane-mediated calcification by novel phosphonates. Calcif Tissue Int 1996;58(5):347-354.

(99) Golomb G. Contemporary approaches for calcitonin therapy. PROC CONTROL RELEASE SOC 1996(23):176-177.

(100) Muller DWM, Gordon D, Topol EJ, Levy RJ, Golomb G. Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. Am Heart J 1996;131(2):211-218.

(101) Schoth R-, Lork E, Seifert FU, Röschenthaler G-, Cohen H, Golomb G, et al. Routes to F3-Etidronic Acid (1-Hydroxy-2,2,2-Trifluoroethylidene-Bisphosphonic Acid), Molecular Structure of the Tris(trimethylsilyl)ester, Antimineralization, and Antiresorption Effects of the Disodium Salt. Naturwissenschaften 1996;83(12):571-574.

(102) Ezra A, Breuer E, Amidon G, Hoffman A, Ornoy A, Patlas N, et al. Peptidyl prodrug of bisphosphonates for improved oral absorption. PROC CONTROL RELEASE SOC 1996(23):83-84.

(103) Golomb G, Van Gelder JM, Alferiev IS, Ornoy A, Hoffman A, Schlossman A, et al. Novel bisphosphonates for calcium-related disorders. Phosphorus Sulfur Silicon Relat Elem 1996;109(1-4):221-224.

(104) Golomb G. Preface. Adv Drug Deliv Rev 1995;17(2):149-150.

(105) Golomb G, Shaked I, Hoffman A. Intrauterine administration of peptide drugs for systemic effect. Adv Drug Deliv Rev 1995;17(2):179-190.

(106) Huffman A, Shaked I, Avramoff A, Golomb G. Pharmacokinetics and pharmacodynamics of trans-endometrial administered peptides and macromolecules. Adv Drug Deliv Rev 1995;17(2):191-203.

(107) Hoffman A, Shaked I, Nyska A, Avramoff A, Golomb G. Trans-endometrial route of drug administration: In-vitro and in-vivo evaluation. PROC CONTROL RELEASE SOC 1995(22):568-569.

(108) Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G. Anticalcification and antiresorption effects of bisacylphosphonates. Bone 1995;16(5):511-520.

(109) Golomb G, Fishbein I, Banai S, Moscovitz D, Mishaly D, Gertz SD, et al. Inhibition of restenosis in a rat model by perivascular delivery of a tyrphostin compound. PROC CONTROL RELEASE SOC 1995(22):151-152.

(110) Hoffman A, Nyska A, Avramoff A, Golomb G. Continuous versus pulsatile administration of erythropoietin (EPO) via the uterus in anemic rats. Int J Pharm 1994;111(2):197-202.

(111) Muller DWM, Golomb G, Gordon D, Levy RJ. Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Coron Artery Dis 1994;5(5):435-442.

(112) Golomb G, Niska A, Avramoff A, Shaked I, Hoffman A. Intrauterine controlled delivery of peptides for systemic effect. PROC CONTROL RELEASE SOC 1994(21):38-39.

(113) Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994;93(3):1243-1249.

(114) Bialer M, Hadad S, Golomb G, Barel S, Samara E, Salach OA, et al. Pharmacokinetic analysis of two new sustained‐release products of diltiazem designed for twice‐and once‐daily treatment. Biopharm Drug Dispos 1994;15(1):45-52.

(115) Breuer E, Golomb G, Hoffman A, Schlossman A, Van Gelder JM, Saadeh H, et al. In Vitro and In Vivo Inhibition of Hydroxyapatite Formation and Dissolution by Bisacylphosphonates and Bishydroxyiminophosphonates. Phosphorus Sulfur Silicon Relat Elem 1993;76(1-4):167-170.

(116) Golomb G, Avramoff A, Hoffman A. A New Route of Drug Administration: Intrauterine Delivery of Insulin and Calcitonin. Pharm Res 1993;10(6):828-833.

(117) Golomb G, Barashi A, Wagner D, Nachmias O. In-vitro and in-vivo models for the study of the relationship between hydrophilicity and calcification of polymeric and collageneous biornaterials. Clin Mater 1993;13(1-4):61-69.

(118) New frontiers in cardiovascular polymeric controlled release. Polymeric Materials Science and Engineering, Proceedings of the ACS Division of Polymeric Materials Science and Engineering; 1992.

(119) Schoen FJ, Golomb G, Levy RJ. Calcification of bioprosthetic heart valves: a perspective on models. J Heart Valve Dis 1992;1(1):110-114.

(120) Golomb G. Calcification of polyurethane-based biomaterials implanted subcutaneously in rats: role of porosity and fluid absorption in the mechanism of mineralization. J Mater Sci: Mater Med 1992;3(4):272-277.

(121) Golomb G, Ezra V. Covalent binding of protamine by glutaraldehyde to bioprosthetic tissue: Characterization and anticalcification effect. Biomater Artif Cells Immobilization Biotechnol 1992;20(1):31-41.

(122) Golomb G, Eitan Y, Hoffman A. Measurement of Serum [3H]Tetracycline Kinetics and Indices of Kidney Function Facilitate Study of the Activity and Toxic Effects of Bisphosphonates in Bone Resorption. Pharm Res 1992;9(8):1018-1023.

(123) Golomb G, Lewinstein I, Ezra V, Schoen FJ. Mechanical properties and histology of charge modified bioprosthetic tissue resistant to calcification. Biomaterials 1992;13(6):353-356.

(124) Golomb G, Schlossman A, Eitan Y, Saadeh H, Van Gelder JM, Breuer E. In vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates. J Pharm Sci 1992;81(10):1004-1007.

(125) Golomb G, Schlossman A, Saadeh H, Levi M, Van Gelder JM, Breuer E. Bisacylphosphonates Inhibit Hydroxyapatite Formation and Dissolution in Vitro and Dystrophic Calcification in Vivo. Pharm Res 1992;9(1):143-148.

(126) Golomb G, Wagner D. Characterization and anticalcification effects of implantable polyurethane matrices containing amorphous dispersion of bisphosphonic acid. Clin Mater 1991;8(1-2):33-42.

(127) Golomb G, Shpigelman A. Prevention of bacterial colonization on polyurethane in vitro by incorporated antibacterial agent. J Biomed Mater Res 1991;25(8):937-952.

(128) Golomb G, Ezra V. Prevention of bioprosthetic heart valve tissue calcification by charge modification: Effects of protamine binding by formaldehyde3. J Biomed Mater Res 1991;25(1):85-98.

(129) Golomb G, Wagner D. Development of a new in vitro model for studying implantable polyurethane calcification. Biomaterials 1991;12(4):397-405.

(130) Golomb G, Fisher P, Rahamim E. The relationship between drug release rate, particle size and swelling of silicone matrices. J Control Release 1990;12(2):121-132.

(131) Levy RJ, Johnston TP, Sintov A, Golomb G. Controlled release implants for cardiovascular disease. J Control Release 1990;11(1-3):245-254.

(132) Johnston TP, Bove EL, Bolling SF, Schoen FJ, Boyd JA, Golomb G, et al. Local controlled release of 1-hydroxyethylidene diphosphonate using silicone-rubber matrices. Effects of sterilization on in vitro release and in vivo efficacy. ASAIO Trans 1988;34(3):835-838.

(133) Golomb G, Schoen FJ, Smith MS, Linden J, Dixon M, Levy RJ. The role of glutaraldehyde-induced cross-links in calcification of bovine pericardium used in cardiac valve bioprostheses. Am J Pathol 1987;127(1):122-130.

(134) Golomb G. Controlled Release of Diphosphonates from Synthetic Polymers to Inhibit Calcification. J Biomater Appl 1987;2(2):266-289.

(135) Golomb G, Dixon M, Smith MS, Schoen FJ, Levy RJ. Controlled‐release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: Release rate modulation with silicone matrices via drug solubility and membrane coating. J Pharm Sci 1987;76(4):271-276.

(136) Golomb G, Dixon M, Smith MS, Schoen FJ, Levy RJ. Inhibition of bioprosthetic heart valve calcification by sustained local delivery of Ca and Na diphosphonate via controlled release matrices. ASAIO Trans 1986;32(1):587-590.

(137) Levy RJ, Shoen FJ, Golomb G. Bioprosthetic heart valve calcification: Clinical features, pathobiology, and prospects for prevention. CRIT REV BIOCOMPAT 1986;2(2):147-187.

(138) Stabholz A, Sela MN, Friedman M, Golomb G, Soskolne A. Clinical and microbiological effects of sustained release chlorhexidine in periodontal pockets. J Clin Periodontol 1986;13(8):783-788.

(139) Golomb G, Langer R, Schoen FJ, Smith MS, Yong Mi Choi, Levy RJ. Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: Dose-response and mechanistic studies. J Control Release 1986;4(3):181-194.

(140) Levy RJ, Golomb G, Wolfrum J, Lund SA, Schoen FJ, Langer R. Local controlled-release of diphosphonates from ethylenevinylacetate matrices prevents bioprosthetic heart valve calcification. Trans Am Soc Artif Intern Organs 1985;31:459-463.

(141) Friedman M, Golomb G, Brayer L. Plaque Inhibition by Sustained Release of Chlorhexidine from Removable Appliances. J Dent Res 1985;64(11):1319-1321.

(142) Friedman M, Brayer L, Golomb G, Hiller H. Prevention of plaque accumulation by local application of a sustained release delivery system of chlorhexidine. J Control Release 1984;1(2):157-160.

(143) HIRSCHFELD Z, FRIEDMAN M, GOLOMB G, BEN‐YAACOV D. New sustained release dosage form of chlorhexidine for dental use: use for plaque control in partial denture wearers. J Oral Rehabil 1984;11(5):477-482.

(144) Golomb G, Friedman M, Soskolne A, Stabholz A, Sela MN. Sustained Release Device Containing Metronidazole for Periodontal Use. J Dent Res 1984;63(9):1149-1153.

(145) Soskolne A, Golomb G, Friedman M, Sela MN. New sustained release dosage form of chlorhexidine for dental use: II. Use in periodontal therapy. J Periodontal Res 1983;18(3):330-336.

(146) Friedman M, Golomb G. New sustained release dosage form of chlorhexidine for dental use: I. Development and kinetics of release. J Periodontal Res 1982;17(3):323-328.

(147) Soskolne WA, Friedman M, Golomb G, Sela M. Sustained release reservoirs of chlorhexidine in periodontal pockets. J Dent Res 1982;61(Abs.).

(148) Friedman M, Golomb G. Dissolution rate of fluorides: Quality test of dentifrices. J Dent Res 1980;59(SPEC.1SS. DI):1879.

(149) Friedman M, Golomb G, Brayer L, Hiller Ch. Sustained release chlorhexidine preparations for topical use. J Dent Res 1980;59(SPEC. ISSUE B).